Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

205
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
205
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

337
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
337
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

394
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
394
Depressive Disorders: MDD and Dysthymia01:27

Depressive Disorders: MDD and Dysthymia

71
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
71
Depressive Disorders: Etiology01:27

Depressive Disorders: Etiology

59
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
59
Depression: Overview01:18

Depression: Overview

228
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
228

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Methodological innovations to advance substance use disorder research: Proceedings of a NIDA workshop on target trial emulation and translational testing of digital health tools.

Journal of substance use and addiction treatment·2026
Same author

Safety of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Longitudinal Analysis.

Drug safety·2026
Same author

Methodological considerations of suicide risk following antipsychotic therapy in treatment-resistant depression.

The British journal of psychiatry : the journal of mental science·2026
Same author

Developing a Hierarchical Algorithm to Identify Pregnancies and Determine Gestational Age from Nationwide Linked Health Data in Taiwan.

Drug safety·2026
Same author

Editorial: Perinatal substance use and maternal mental health.

Frontiers in psychiatry·2026
Same author

Risk of skin cancer from hydrochlorothiazide and other diuretics across races: A global cohort study.

Environmental toxicology and pharmacology·2026

Related Experiment Video

Updated: Jun 15, 2025

Exergaming in Older People Living with HIV Improves Balance, Mobility and Ameliorates Some Aspects of Frailty
07:27

Exergaming in Older People Living with HIV Improves Balance, Mobility and Ameliorates Some Aspects of Frailty

Published on: October 6, 2016

10.2K

Injurious Fall Risk Differences Among Older Adults With First-Line Depression Treatments.

Grace Hsin-Min Wang1, Edward Chia-Cheng Lai2, Amie J Goodin1

  • 1Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville.

JAMA Network Open
|August 26, 2024
PubMed
Summary
This summary is machine-generated.

First-line antidepressants, excluding psychotherapy, were linked to a lower risk of falls and related injuries in older adults with depression. This suggests a potentially safer profile than previously thought for these common treatments.

More Related Videos

Author Spotlight: Innovations in iTUG Test for Enhanced Risk Assessment and Cognitive Insights
05:26

Author Spotlight: Innovations in iTUG Test for Enhanced Risk Assessment and Cognitive Insights

Published on: October 25, 2024

961
Community-based Adapted Tango Dancing for Individuals with Parkinson's Disease and Older Adults
09:19

Community-based Adapted Tango Dancing for Individuals with Parkinson's Disease and Older Adults

Published on: December 9, 2014

25.6K

Related Experiment Videos

Last Updated: Jun 15, 2025

Exergaming in Older People Living with HIV Improves Balance, Mobility and Ameliorates Some Aspects of Frailty
07:27

Exergaming in Older People Living with HIV Improves Balance, Mobility and Ameliorates Some Aspects of Frailty

Published on: October 6, 2016

10.2K
Author Spotlight: Innovations in iTUG Test for Enhanced Risk Assessment and Cognitive Insights
05:26

Author Spotlight: Innovations in iTUG Test for Enhanced Risk Assessment and Cognitive Insights

Published on: October 25, 2024

961
Community-based Adapted Tango Dancing for Individuals with Parkinson's Disease and Older Adults
09:19

Community-based Adapted Tango Dancing for Individuals with Parkinson's Disease and Older Adults

Published on: December 9, 2014

25.6K

Area of Science:

  • Gerontology
  • Psychiatry
  • Epidemiology

Background:

  • Depression affects one-third of older US adults, commonly treated with psychotherapy and antidepressants.
  • Prior research on antidepressant-associated falls and injuries may be biased by confounding factors.
  • Falls and related injuries (FRI) pose a significant health risk to the elderly population.

Purpose of the Study:

  • To investigate the association between first-line depression treatments and the risk of falls and related injuries (FRI) in older adults.
  • To provide evidence-based insights into the safety of antidepressant medications in geriatric depression management.

Main Methods:

  • A cohort study utilizing a target trial emulation framework with cloning-censoring-weighting on Medicare claims data (2016-2019).
  • Inclusion of fee-for-service beneficiaries aged 65+ with newly diagnosed depression.
  • Analysis of one-year FRI rates, restricted mean survival time (RMST), and adjusted hazard ratios (aHR).

Main Results:

  • Among 101,953 participants, psychotherapy was not associated with FRI risk (aHR, 0.94).
  • First-line antidepressants, excluding psychotherapy, showed a decreased FRI risk (aHR range: 0.74 for bupropion to 0.83 for escitalopram) compared to untreated individuals.
  • FRI incidence was lower with bupropion (63/1000 person-years) than for untreated individuals (87/1000 person-years).

Conclusions:

  • First-line antidepressants, when used for depression in older adults, were associated with a reduced risk of falls and related injuries.
  • These findings challenge previous concerns and highlight a potentially favorable safety profile for these medications in this demographic.
  • The study aids clinicians in making informed decisions regarding depression treatment for older adults, considering both efficacy and safety outcomes.